Long COVID affects a large global population and is associated with reduced quality of life. The authors note that nearly all completed Long COVID clinical trials to date have reported no benefit and that requiring participant travel to study sites systematically excludes more severely affected patients. Given the existence of many candidate therapeutics with established safety profiles and prior regulatory approvals for other indications, the investigators designed a trial to efficiently evaluate one such candidate—tirzepatide—for fatigue in Long COVID using an entirely remote, direct-to-participant model.
The study is a double-blind, placebo-controlled, phase 2 randomized trial. The distinguishing feature is an entirely decentralized infrastructure intended to remove geographic and mobility barriers to participation. Key design elements included electronic informed consent, centralized management of study drug distribution, and remote collection of clinical and behavioral data using participant-owned devices and study-provided tools.
The trial operates under an FDA Investigational New Drug (IND) authorization. Ethical review and approval were provided by the Scripps Institutional Review Board. The authors confirm that participant consent processes and institutional approvals were followed and that the trial was registered (ClinicalTrials.gov identifier provided in the source). The source also notes declarations of competing interests for some authors and employees of collaborating organizations.
Several specific operational elements enabled the siteless trial execution:
These components were designed to support blinding, maintain trial integrity, and enable participation from individuals who might not be able to travel to study sites.
Enrollment metrics reported in the source emphasize the trial’s rapid accrual and the severity of illness among participants:
The authors interpret these baseline measures to indicate a more severely affected population than other clinical trials that collected comparable data.
According to the report, the trial processes are functioning as designed. The decentralized model enabled rapid recruitment and inclusion of participants who are often excluded by site-based designs, including those with severe functional impairment. Participants used existing advocacy and support channels to find and communicate about the study, supporting outreach and engagement.
The authors highlight that central cold-chain distribution and remote verification workflows permitted delivery and administration of an injectable investigational product while maintaining double-blinding.
The investigators conclude that a direct-to-participant, siteless infrastructure can feasibly support a double-blind, placebo-controlled trial of an injectable drug at scale and accelerate accrual while reaching more severely affected participants. They argue that modernization of drug distribution and regulatory pathways will be necessary to unlock the full potential of decentralized infrastructure for clinical trials focused on drug repurposing.
This approach is presented as particularly relevant for conditions like Long COVID, where many candidate therapeutics already have established safety profiles in other indications and where traditional site-based trials have struggled to recruit or to include the most affected patients.
Data from this study are part of an ongoing, blinded clinical trial and will be made available with the publication of the trial results. The source lists the ClinicalTrials.gov identifier and declares funding from the Schmidt Initiative for Long COVID and NIH support. Competing interests declared in the source include employment and shareholding relationships for named contributors.
The source is a preprint that has not been peer reviewed and explicitly states that findings should not be used to guide clinical practice. Outcome data beyond enrollment and baseline characteristics are not reported in the abstract; efficacy and safety results remain blinded and pending final trial analyses.